Skip to main content

CORRECTION article

Front. Immunol., 13 June 2022
Sec. Viral Immunology
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.948031

Corrigendum: Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

This article is a correction to:

  1. Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

    1. Read original article
Mark B. Carascal,&#x;Mark B. Carascal1,2†Rance Derrick N. Pavon&#x;Rance Derrick N. Pavon1†Windell L. Rivera*Windell L. Rivera1*
  • 1Pathogen-Host-Environment Interactions Research Laboratory, Institute of Biology, College of Science, University of the Philippines Diliman, Quezon City, Philippines
  • 2Clinical and Translational Research Institute, The Medical City, Pasig City, Philippines

A Corrigendum on
Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

By Carascal MB, Pavon RDN and Rivera WL (2022) Front. Immunol. 13:878943. doi: 10.3389/fimmu.2022.878943

In the original article, there was a mistake in Figure 4 as published. An old version of Figure 4 was used instead of the latest figure file. The corrected Figure 4 appears below.

FIGURE 4
www.frontiersin.org

Figure 4 General construction process of recombinant protein, DNA, VLP, vector-based, and mRNA influenza vaccines.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: heterosubtypic immunity, influenza, influenza antigen, recombinant vaccine, universal vaccine

Citation: Carascal MB, Pavon RDN and Rivera WL (2022) Corrigendum: Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response. Front. Immunol. 13:948031. doi: 10.3389/fimmu.2022.948031

Received: 19 May 2022; Accepted: 24 May 2022;
Published: 13 June 2022.

Edited and reviewed by:

Huan Nguyen, IGY Life Sciences, Canada

Copyright © 2022 Carascal, Pavon and Rivera. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Windell L. Rivera, wlrivera@science.upd.edu.ph

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.